Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00005810

Run by

Alliance for Clinical Trials in Oncology

People needed

40

Starts

2000-03-01

Expected to finish

2006-06-01

Last updated by the study team

2016-07-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Marlene & Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Norris Cotton Cancer Center — Lebanon, New Hampshire, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Lineberger Comprehensive Cancer Center, UNC — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.